Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy

Abstract

No significant differences were observed in the splenic volume of those showing clinical benefit versus those without clinical benefit to pembrolizumab treatment in NSCLC patients. CT splenic volume cannot be used as a potentially simple biomarker of response to immunotherapy.